Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip Company Of The Year Celgene In Rude Health Despite Hiccups

Executive Summary

Celgene, which continues to plough back a very high proportion of its revenues into R&D, remains the preferred partner of choice for biotechs who hope to bring the next wave of innovative products to the market, Kevin Loth, VP of corporate affairs and policy in Europe tells Scrip.

Advertisement

Related Content

Which Biotechs Enjoyed A 'JPM Jump' - And Which Lost Out?
What's New And What's Next In CAR-T After ASH
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Put Yourself In The CEO’s Shoes: Audience Makes Drug Pricing And Investment Decisions At EHFG
Celgene Plots Blockbuster Course For Ozanimod
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100210

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel